Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
adjourned, Administracion, aforementioned, ALK, Allergan, Amneal, antitoxin, Appraisal, attainment, baseline, bezlotoxumab, bromide, CAFC, calcitonin, carbapenem, cCAM, CGRP, checkpoint, choose, claimant, Complementario, compliant, conference, counterclaimed, cured, CV, Darmstadt, decentralized, deconsolidated, Dificid, discharge, draft, dropped, dysmenorrhea, Ebola, EGFR, Elkton, EMD, emetogenic, equitable, ERISA, escrow, esophageal, EUAL, Excellence, expression, Fl, foregoing, formulary, Freda, French, frequency, futility, genomic, GERBERDING, German, GT, Harbor, IDO, improperly, IOmet, ipragliflozin, Irish, KGaA, Kotobuki, licensee, Lifetec, likewise, Los, MACE, macroeconomic, Marizev, Matrix, metabolism, microsatellite, Mundipharma, myeloma, newer, NewLink, NICE, Noncompliance, noncurrent, nonfatal, NSCLC, Oxford, PDUFA, peptide, percent, postcombination, precombination, prequalification, Prestige, quantification, Ratification, reacquire, readily, reassigned, referenced, Regumate, relebactam, relied, repaid, repeat, restated, revalued, ribavirin, RNA, Sagent, Savior, Shanghai, Shield, simplification, strongest, TDO, testicular, tradename, transatlantic, unaudited, unblinded, unfair, verubecestat, Virginia, virologic, waiver, Wolfson, word, wrongdoing, Zealand, Zepatier
Removed:
AA, ABP, aggregated, anesthesiology, arising, asenapine, asleep, averaging, AWP, AzaSite, bruce, calculating, Canadian, certify, Chairman, collecting, contend, conventional, CRA, creditable, decided, diversify, dorzolamide, doxorubicin, DSMB, enabled, Endocyte, enrolled, factor, falling, Greece, hire, hydrochloride, hypersensitivity, inactionable, includable, induce, infusion, insolvency, insomnia, Inspire, Integrilin, investigated, Israel, Joel, KBC, kuhlik, length, liposomal, Lundbeck, macro, maleate, manipulation, Maxalt, merged, misleading, moved, muscle, ordering, Organon, outlook, passed, pegylated, pollen, preferential, premium, purported, ragweed, referral, regimen, relaxation, removed, RNAi, rural, solution, staying, sublingual, suspend, suvorexant, undistributed, uptake, vaniprevir, variability, vintafolide, vorapaxar
Filing tables
Filing exhibits
- 10-K Annual report
- 10.20 Exhibit 10.20: 2015 Nqso Grants Under Merck Co Inc. 2010 Incentive Stock Plan
- 10.21 Exhibit 10.21: 2015 Psu Award Terms Under Merck Co Inc 2010 Stock Incentive Plan
- 10.22 Exhibit 10.22: 2015 Rsu Grants Under Merck Co Inc 2010 Incentive Stock Plan
- 12 Exhibit 12: Computation of Ratios of Earnings to Fixed Charges
- 21 Exhibit 21: Subsidiary List
- 23 Exhibit 23: Consent of Independent Registered Public Accounting Firm
- 24.1 Ex 24.1: Power of Attorney
- 24.2 Exhibit 24.2: Certification of Board Resolution
- 31.1 Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification of CEO
- 31.2 Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification of CFO
- 32.1 Exhibit 32.1: Section 1350 Certification of CEO
- 32.2 Exhibit 32.2: Section 1350 Certification of CFO
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links
Exhibit 24.1
POWER OF ATTORNEY
Each of the undersigned does hereby appoint MICHAEL J. HOLSTON as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2015 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith.
IN WITNESS WHEREOF, this instrument has been duly executed as of the 26th day of February 2016.
MERCK & CO., Inc.
| /s/ Kenneth C. Frazier | Chairman, President and Chief Executive Officer | |
| Kenneth C. Frazier | (Principal Executive Officer; Director) | |
| /s/ Robert M. Davis | Executive Vice President and Chief Financial Officer | |
| Robert M. Davis | (Principal Financial Officer) | |
| /s/ Rita A. Karachun | Senior Vice President Finance—Global Controller | |
| Rita A. Karachun | (Principal Accounting Officer) | |
DIRECTORS
| /s/ Leslie A. Brun | /s/ Carlos E. Represas | |
| Leslie A. Brun | Carlos E. Represas | |
| /s/ Thomas R. Cech | /s/ Paul B. Rothman | |
| Thomas R. Cech | Paul B. Rothman | |
| /s/ Pamela J. Craig | /s/ Patricia F. Russo | |
| Pamela J. Craig | Patricia F. Russo | |
| /s/ Thomas H. Glocer | /s/ Craig B. Thompson | |
| Thomas H. Glocer | Craig B. Thompson | |
| /s/ William B. Harrison, Jr. | /s/ Wendell P. Weeks | |
| William B. Harrison, Jr. | Wendell P. Weeks | |
| /s/ C. Robert Kidder | /s/ Peter C. Wendell | |
| C. Robert Kidder | Peter C. Wendell | |
| /s/ Rochelle B. Lazarus | ||
| Rochelle B. Lazarus | ||